NT5C1A抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P01604(NT5C1A Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P01604(NT5C1A Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The NT5C1A antibody targets the cytosolic 5'-nucleotidase IA (NT5C1A), an enzyme encoded by the *NT5C1A* gene, which plays a critical role in nucleotide metabolism by catalyzing the dephosphorylation of purine and pyrimidine nucleoside monophosphates. This enzyme regulates intracellular nucleotide pools, influencing cellular processes like proliferation, energy homeostasis, and signaling. NT5C1A has garnered attention in both cancer and autoimmune disease research. In oncology, its overexpression is linked to chemoresistance in acute lymphoblastic leukemia (ALL) and melanoma, potentially due to altered nucleotide salvage pathways.

Notably, NT5C1A is a major autoantigen in sporadic inclusion body myositis (sIBM), a chronic inflammatory muscle disorder. Autoantibodies against NT5C1A are detected in ~50% of sIBM patients, serving as a diagnostic biomarker to differentiate sIBM from other myopathies. Research suggests these antibodies may contribute to disease pathogenesis by disrupting enzymatic activity or promoting intracellular protein aggregation.

NT5C1A antibodies, including monoclonal and polyclonal variants, are widely used in research to study protein expression, localization, and function via techniques like Western blotting, immunohistochemistry, and ELISA. Their specificity and validation across species (e.g., human, mouse) make them essential tools for exploring NT5C1A's role in cellular homeostasis, disease mechanisms, and therapeutic targeting.